Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis
ObjectiveTo compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.MethodsWe retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.1047595/full |
| _version_ | 1797984064760709120 |
|---|---|
| author | Xuemei Tao Xuemei Tao Changjing Xu Xiaoyan Zhong Yao Mou Jingwei Li Xuping Yang Yilan Huang Yilan Huang |
| author_facet | Xuemei Tao Xuemei Tao Changjing Xu Xiaoyan Zhong Yao Mou Jingwei Li Xuping Yang Yilan Huang Yilan Huang |
| author_sort | Xuemei Tao |
| collection | DOAJ |
| description | ObjectiveTo compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.MethodsWe retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity score matching (PSM) analysis was used to reduce the actual baseline difference between groups.Results416 patients participated in the analysis after PSM (Biapenem: Meropenem = 1:1). For the Biapenem group and Meropenem group, the effective rates were 90.4% and 90.9%, respectively (p = 1.0) and the incidence of adverse reactions were 7.7% and 7.2%, respectively (p = 1.0). There were no statistical differences between Biapenem and Meropenem.ConclusionIn general, the efficacy and safety of Biapenem are comparable to Meropenem in the treatment of children with SCAP. |
| first_indexed | 2024-04-11T06:55:44Z |
| format | Article |
| id | doaj.art-5ff6397e99604bbe8d354cf3982f6b39 |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-11T06:55:44Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-5ff6397e99604bbe8d354cf3982f6b392022-12-22T04:39:02ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602022-11-011010.3389/fped.2022.10475951047595Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysisXuemei Tao0Xuemei Tao1Changjing Xu2Xiaoyan Zhong3Yao Mou4Jingwei Li5Xuping Yang6Yilan Huang7Yilan Huang8Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaSchool of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaSchool of Pharmacy, Southwest Medical University, Luzhou, ChinaObjectiveTo compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.MethodsWe retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity score matching (PSM) analysis was used to reduce the actual baseline difference between groups.Results416 patients participated in the analysis after PSM (Biapenem: Meropenem = 1:1). For the Biapenem group and Meropenem group, the effective rates were 90.4% and 90.9%, respectively (p = 1.0) and the incidence of adverse reactions were 7.7% and 7.2%, respectively (p = 1.0). There were no statistical differences between Biapenem and Meropenem.ConclusionIn general, the efficacy and safety of Biapenem are comparable to Meropenem in the treatment of children with SCAP.https://www.frontiersin.org/articles/10.3389/fped.2022.1047595/fullBiapenemsevere community-acquired pneumoniapropensity score matching methodchildrenefficacysafety |
| spellingShingle | Xuemei Tao Xuemei Tao Changjing Xu Xiaoyan Zhong Yao Mou Jingwei Li Xuping Yang Yilan Huang Yilan Huang Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis Frontiers in Pediatrics Biapenem severe community-acquired pneumonia propensity score matching method children efficacy safety |
| title | Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis |
| title_full | Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis |
| title_fullStr | Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis |
| title_full_unstemmed | Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis |
| title_short | Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis |
| title_sort | real world biapenem vs meropenem in the treatment of severe community acquired pneumonia in children a propensity score matching analysis |
| topic | Biapenem severe community-acquired pneumonia propensity score matching method children efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fped.2022.1047595/full |
| work_keys_str_mv | AT xuemeitao realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT xuemeitao realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT changjingxu realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT xiaoyanzhong realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT yaomou realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT jingweili realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT xupingyang realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT yilanhuang realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis AT yilanhuang realworldbiapenemvsmeropeneminthetreatmentofseverecommunityacquiredpneumoniainchildrenapropensityscorematchinganalysis |